| ￥2300 | |
| Z04220-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 17.07kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 24-27kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | CLEC2C (CD69) is a membrane-bound, type II C-lectin receptor and acts as a costimulatory molecule for T cell activation and proliferation. It is involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets. CLEC2C is a disulfide-linked homodimer protein with two differentially glycosylated subunits. |
| Synonyms | CD69; CLEC2C; EA1; BL-AC/P26; AIM; BL-AC; P26; GP32; 28; MLR-3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
